Reprogram Biosciences develops mRNA-encoded gene-combination therapeutics intended to reprogram tumor cells in situ to induce antigen-presenting function and activate antitumor immunity. The company uses an AI discovery engine, CellRecodeX, which integrates biological foundation models to identify and prioritize therapeutic reprogramming candidates and support pipeline expansion. Reprogram is focused on treating solid tumors with high unmet need and is operating at the preclinical stage. The team reports accelerated progress—advancing from concept to in vivo data within six months. Current plans funded by the seed round include advancing the lead program, expanding CellRecodeX, and supporting CMC activities. Founded in 2025, the company is based in San Carlos, California and has raised a total of $6 million to date.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

May 2026